Related Experiment Video
Updated: Aug 10, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Smoking-related lung disease: prospects for new drug therapy
1National Heart and Lung Institute's Clinical Studies Unit, Royal Brompton Hospital, London, UK.
Abstract:
The first 2001 meeting of the Society for Medicines Research, held in London on March 14, was devoted to emerging treatments for chronic obstructive pulmonary disease, commonly referred to as smoking-related lung disease or COPD. As COPD afflicts more and more people around the world, the dual need for preventative measures and therapeutic approaches will also continue to grow. During this sobering yet inspiring symposium, researchers looked at compounds that are currently in phase III clinical studies; reactive oxidant species, proteases and neutrophil chemotactics as therapeutic targets; and finally, the potential of monoclonal antibodies and retinoids.
More Related Videos
Related Concept Videos
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease II: Emphysema
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

